Skip to main content
. Author manuscript; available in PMC: 2014 Oct 2.
Published in final edited form as: Xenobiotica. 2011 Sep 5;41(11):972–987. doi: 10.3109/00498254.2011.598582

Table 1.

Compound list for all macro-molecule drugs.

Compounds MW (kDa) Observed CL (Mean (CV%), ml/hr/kg) in human a b Reference Group
1 Abciximab 47.6 288 (59) (Abernethy et al., 2002) 1
2 Alefacept 51.8 0.25 (Tang et al., 2004)
3 Alteplasea 67.5 894 (14) 34.8 0.863 (Martin et al., 1991, Martin et al., 1992)
4 ANFa 67.5 2229 (11) 112 0.847 (Yandle et al., 1986, Cernacek et al., 1988, Krieter and Trapani, 1989, Marleau et al., 1989)
5 BM06.022a 39.0 239 (13) 6.98 0.893 (Martin et al., 1991)
6 Cetrorelix 1.49 72 (Obach et al., 2008)
7 Cyclosporina 1.20 321 (38) 5.51 1.15 (Sangalli et al., 1988)
8 Dalbavancin 1.82 0.61 (3.6) (Obach et al., 2008)
9 Daptomycin 1.62 9.0 (10) (Obach et al., 2008)
10 Darbepoetin alfa 37.1 2.3 (35) (Egrie Jc Fau - Dwyer et al., 2003)
11 Denileukin diftitox 57.6 105 (20) (Tang et al., 2004)
12 Desmopressin 1.07 143 (34) (Agerso H Fau - Seiding Larsen et al.)
13 Digoxin-Faba 45.5 19 (32) 1.017 0.667 (Grene-Lerouge Na Fau - Bazin-Redureau et al., 1996, Ujhelyi and Robert, 1995)
14 Drotrecogin-α 55.0 314 (31) (Olsen and Martin, 2002)
15 EPO-α 30.4 8.1 (12) (Halstenson et al., 1991)
16 EPO-βa 36.0 7.9 (15) 0.234 0.660 (Bleuel et al., 1996, Halstenson et al., 1991)
17 Factor IXa 56.5 9.1 (16) 0.288 0.715 (Keith et al., 1995, McCarthy et al., 2002, White et al., 1998)
18 Filgrastim 18.8 36 (24) (Tang et al., 2004)
19 GLQ223b 27.0 130 (54) (Gatti et al., 1991)
20 Glucagon 3.50 810 (Tang et al., 2004)
21 IFNβ1aa 22.5 573 (47) 4.98 0.907 (Kagan et al., 2010)
22 IFNβ1bb 18.5 760 (37) (Kagan et al., 2010)
23 ISIS 2503a NA 144 2.41 0.879 (Geary et al., 2001)
24 ISIS 3521a 6.72 67 (2.7) 2.12 0.599 (Geary et al., 2001)
25 ISIS 5132a 6.63 76 (32) 3.23 0.873 (Geary et al., 2001)
26 ISIS 104838a 7.41 41 (12) 155 0.709 (Sewell et al., 2002, Geary et al., 2003)
27 ISIS 301012b 7.39 41 (12) 96.8 0.487 (Yu et al., 2007)
28 Leuprolide 1.21 114 (7.4) (Obach et al., 2008)
29 Nartograstima 19 29 (11) 49.2 0.655 (Kuwabara et al., 1994, Ohdo et al., 1998)
30 Octreotide 1.00 121 (25) (Tang et al., 2004)
31 Pamiteplasea 37.0 130 (7.7) 2.06 0.913 (Oikawa et al., 2000, Oikawa et al., 2001)
32 PEG-EPOa 60.0 0.50 (6.0) 1.95 0.674 (Macdougall et al., 2006)
33 PEG-IL2a 22.0 6.0 0.179 0.750 (Braeckman, 2000)
34 rCD4a 50.0 49 (43) 3.36 0.577 (Mordenti et al., 1991)
35 Relaxina 6.00 139 (37) 5.83 0.776 (Mordenti et al., 1991)
36 rEPOa 36.0 10.1 (35) 0.221 0.921 (Flaharty et al., 1990, Woo and Jusko, 2007)
37 Reteplase 39.6 300 (40) (Tang et al., 2004)
38 rhGHa 20.0 124 6.47 0.688 (Mordenti et al., 1991)
39 rhIL-2a 15.0 165 (54) 4.79 0.650 (Braeckman, 2000)
40 rHirudina 6.91 168 8.48 1.01 (Nowak, 1991)
41 rHuIFN-αAa 19.0 169 (38) 3.68 0.710 (Lave et al., 1995)
42 rHuIL-10 18.0 65 (11) (Radwanski et al., 1998)
43 rt-PAa 63.0 490 16.2 0.862 (Mordenti et al., 1991, Collen et al., 1991)
44 SK&F 107647 1.17 65 (28) (Brocks et al., 1996)
45 SR 90107Aa 1.11 6.3 (16) 41.2 0.506 (Herault et al., 1997)
46 Teicoplanin A2-1 1.88 12 (5.0) (Obach et al., 2008)
47 Telavancin 1.76 12 (12) (Obach et al., 2008)
48 Tenecteplasea 59.0 83 (14) 3.35 0.903 (Tanswell et al., 2002)
49 Valspodar 1.22 156 (Obach et al., 2008)
50 Vancomycin 1.45 112 (5.4) (Obach et al., 2008)
51 Abatacepta 92.0 0.23 0.563 0.647 (Srinivas et al., 1997, Srinivas et al., 1996a, Srinivas et al., 1996b) 2
52 Adalimumabb 148 0.13 (31) (Lobo et al., 2004, Weisman et al., 2003)
53 Basiliximab 144 0.59 (46) (Tang et al., 2004)
54 Bevacizumaba 149 0.12 (42) 0.0046 0.684 (Lin et al., 1999, Gordon et al., 2001)
55 CD4-IgGa 98.0 1.9 0.102 0.740 (Mordenti et al., 1991)
56 Cetuximabb 146 0.50 (37) (Lobo et al., 2004)
57 CNTO136b NA 0.19 (32) (Ling et al., 2009)
58 CNTO328b 145 0.47 (34) (Ling et al., 2009, Puchalski et al.)
59 CNTO95b 180 0.28 (13) (Ling et al., 2009, Mullamitha et al., 2007)
60 Daclizumabb 143 0.19 (Tang et al., 2004, Ling et al., 2009)
61 Eculizumab 148 0.29 (12) #
62 Efalizumabb 150 0.65 (32) (Ling et al., 2009, Bauer et al., 1999)
63 EGFr3a 150 0.98 (18) 0.0865 1.02 (Crombet et al., 2001)
64 Factor VIIIa 340 3.0 0.182 0.744 (Mordenti et al., 1996, Stokol et al., 1997)
65 Gemtuzumab 152 3.3 (85) (Dowell et al., 2001)
66 Golimumabb 147 0.28 (79) (Ling et al., 2009)
67 Horse F(ab′)2a 100 0.93 (84) 0.0328 0.534 (Bazin-Redureau et al., 1998, Ho et al., 1990)
68 Infliximaba 144 0.14 (20) 0.0075 0.540 (Tang et al., 2004, Palframan R Fau - Airey et al., 2009, Rojas et al., 2005)
69 Laronidase 83.0 132 (32) (Tang et al., 2004)
70 Lenercepta 120 0.30 0.008 1.06 (Richter Wf Fau - Gallati et al., 1999)
71 Natalizumabb 149 0.27 (1.5) (Ling et al., 2009, Sheremata et al., 1999)
72 Panitumumabb 147 0.20 (10) (Ling et al., 2009, Cohenuram and Saif, 2007)
73 Pertuzumaba 150 0.14 (36) 0.259 0.926 (Agus et al., 2005, Adams et al., 2006)
74 Rituximab 145 0.13 (Cartron et al., 2007)
75 RSHZ19a 146 0.122 (15) 0.0035 0.731 (Davis et al., 1995, Everitt et al., 1996)
76 Tanezumabb 145 0.11 #
77 Tositumomab 144 0.97 (Lobo et al., 2004)
78 Trastuzumabb 146 0.41 (61) (Tang et al., 2004, Ling et al., 2009)
79 Ustekinumabb 146 0.093 (28) (Ling et al., 2009)
80 Veltuzumab 145 0.093 (39) (Morschhauser et al., 2009, Goldenberg et al., 2009)
a

PK data available in ≥ 3 animal species and in human.

b

PK data available in monkey and human.